Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C. Kazuhiko Mishima , Ryo Nishikawa , Yoshitaka Narita , Junki Mizusawa , Minako Sumi , Tomoyuki Koga , Nobuyoshi Sasaki , Manabu Kinoshita , Motoo Nagane , Yoshiki Arakawa , Koji Yoshimoto , Ichiyo Shibahara , Naoki Shinojima , Kenichiro Asano , Takao Tsurubuchi , Hikaru Sasaki , Akio Asai , Takashi Sasayama , Yasutomo Momii , Atsushi Sasaki , Shigeo Nakamura , Masaru Kojima , Junichi Tamaru , Kazuhiro Tsuchiya , Miho Gomyo , Kayoko Abe , Manabu Natsumeda , Fumiyuki Yamasaki , Hiroshi Katayama , Haruhiko Fukuda Neuro-oncology（2022）
摘要
This study failed to demonstrate the benefit of concomitant and maintenance TMZ in newly diagnosed PCNSL.
更多 查看译文
关键词
MGMT, primary central nervous system lymphoma, temozolomide
AI 理解论文
溯源树
样例
